Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRANDON LENOX

Allopathic & Osteopathic Physicians Anesthesiology

NPI
1710023098
CMS profile
469116
Location
MAITLAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$289.02

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $289.02 3

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Biogen, Inc. $186.49 2
EISAI INC. $102.53 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRANDON LENOX

NPI 1710023098 · CMS profile ID 469116

Allopathic & Osteopathic Physicians / Anesthesiology

MAITLAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710023098?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRANDON LENOX, NPI 1710023098, CMS profile ID 469116. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710023098?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). BRANDON LENOX, NPI 1710023098, CMS profile ID 469116. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710023098?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
BRANDON LENOX, NPI 1710023098, CMS profile ID 469116, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1710023098?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $289.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $133.9511/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923419145 CMS
EISAI INC. $102.5308/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926012983 CMS
Biogen, Inc. $52.5407/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923408651 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11.87 1
PY2021 $14.90 1
PY2022 $289.02 3
PY2023 $141.36 2
PY2024 $2,161.67 16
PY2025 $3,301.84 7

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $13,276,611.80 216
PY2024 Principal investigator $6,638,229.38 94
PY2023 Recipient $18,535.52 1
PY2023 Principal investigator $6,796,584.13 63
PY2022 Recipient $75,198.00 3
PY2022 Principal investigator $5,184,921.00 42
PY2021 Recipient $4,330.51 1
PY2021 Principal investigator $6,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

216 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $759.27 12/26/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007912
Principal investigator 1 Janssen Research & Development, LLC $16,745.00 12/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423953
Principal investigator 1 Janssen Research & Development, LLC $3,662.00 12/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424319
Principal investigator 1 Genentech, Inc. $2,154.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568801
Principal investigator 1 Eli Lilly and Company $51,351.00 12/18/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PK AND PD OF LY4006895 IN HEALTHY VOLUNTEERS AND PATIENTS WITH EARLY SYMPTOMATIC AD No dispute reported 06/30/2026 1187883892
Principal investigator 1 ModernaTX, Inc. $5,568.00 12/17/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007924
Principal investigator 1 Janssen Research & Development, LLC $256.00 12/15/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175423862
Principal investigator 1 Janssen Research & Development, LLC $1,812.00 12/15/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423910
Principal investigator 1 Janssen Research & Development, LLC $223.00 12/15/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423929
Principal investigator 1 Janssen Research & Development, LLC $446.00 12/15/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423958
Principal investigator 1 Janssen Research & Development, LLC $5,400.00 12/15/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175423982
Principal investigator 1 Janssen Research & Development, LLC $3,850.00 12/15/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424007
Principal investigator 1 Janssen Research & Development, LLC $5,780.00 12/15/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424230
Principal investigator 1 Janssen Research & Development, LLC $11,560.00 12/15/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424254
Principal investigator 1 Janssen Research & Development, LLC $1,800.00 12/15/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424470
Principal investigator 1 Eli Lilly and Company $996.46 12/14/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187884316
Principal investigator 1 Genentech, Inc. $7,742.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568848
Principal investigator 1 Janssen Research & Development, LLC $404.00 12/01/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424062
Principal investigator 1 Janssen Research & Development, LLC $669.00 12/01/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424434
Principal investigator 1 Janssen Research & Development, LLC $225.00 12/01/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424531
Principal investigator 1 ModernaTX, Inc. $8,177.00 11/27/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007872
Principal investigator 1 ModernaTX, Inc. $11,800.65 11/26/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007866
Principal investigator 1 ModernaTX, Inc. $90.10 11/26/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007896
Principal investigator 1 ModernaTX, Inc. $116.00 11/26/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007916
Principal investigator 1 Genentech, Inc. $2,049.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567858
Principal investigator 1 Eli Lilly and Company $1,020.92 11/19/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY4065967 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187887076
Principal investigator 1 Genentech, Inc. $3,485.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567986
Principal investigator 1 Eli Lilly and Company $50,505.64 11/12/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF BRENIPATIDE COMPARED WITH PLACEBO FOR THE TREATMENT OF ADULT PARTICIPANTS WITH ALCOHOL USE DISORDER (RENEW-ALC-2) No dispute reported 06/30/2026 1187884362
Principal investigator 1 Eli Lilly and Company $122,203.12 11/12/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF BRENIPATIDE COMPARED WITH PLACEBO FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ALCOHOL USE DISORDER (RENEW-ALC-1) No dispute reported 06/30/2026 1187885594
Principal investigator 1 Eli Lilly and Company $36,325.90 11/12/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF BRENIPATIDE COMPARED WITH PLACEBO FOR REDUCTION IN RISK OF RELAPSE TO CIGARETTE SMOKING IN ADULTS (RENEW-SMK-1) No dispute reported 06/30/2026 1187885814
Principal investigator 1 Genentech, Inc. $2,154.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567667
Principal investigator 1 Genentech, Inc. $4,641.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567784
Principal investigator 1 Genentech, Inc. $2,813.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567970
Principal investigator 1 Genentech, Inc. $3,990.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568215
Principal investigator 1 Genentech, Inc. $5,359.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568271
Principal investigator 1 Genentech, Inc. $718.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568523
Principal investigator 1 Genentech, Inc. $2,154.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568543
Principal investigator 1 Genentech, Inc. $500.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568600
Principal investigator 1 Genentech, Inc. $1,436.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568609
Principal investigator 1 Genentech, Inc. $2,082.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568722
Principal investigator 1 Janssen Research & Development, LLC $7,046.00 11/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175423878
Principal investigator 1 Janssen Research & Development, LLC $92.00 10/30/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424501
Principal investigator 1 Eli Lilly and Company $88,792.80 10/23/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PK AND PD OF LY4006895 IN HEALTHY VOLUNTEERS AND PATIENTS WITH EARLY SYMPTOMATIC AD No dispute reported 06/30/2026 1187885816
Principal investigator 1 Janssen Research & Development, LLC $11,265.00 10/23/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424175
Principal investigator 1 Janssen Research & Development, LLC $2,423.00 10/23/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424326
Principal investigator 1 Janssen Research & Development, LLC $1,250.00 10/23/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424525
Principal investigator 1 Janssen Research & Development, LLC $18,732.00 10/20/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424376
Principal investigator 1 Janssen Research & Development, LLC $8,251.00 10/17/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423784
Principal investigator 1 Janssen Research & Development, LLC $3,345.00 10/17/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423895
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $263.00 10/08/2025 Non-covered Recipient Entity
K2 Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease No dispute reported 06/30/2026 1235996403
Principal investigator 1 ModernaTX, Inc. $824.38 09/29/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007900
Principal investigator 1 Janssen Research & Development, LLC $41,215.00 09/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423749
Principal investigator 1 Janssen Research & Development, LLC $3,568.00 09/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424313
Principal investigator 1 Janssen Research & Development, LLC $5,050.00 09/05/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424170
Principal investigator 1 Genentech, Inc. $1,409.00 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566998
Principal investigator 1 Janssen Research & Development, LLC $129.00 08/29/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424017
Principal investigator 1 Janssen Research & Development, LLC $892.00 08/28/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424208
Principal investigator 1 Janssen Research & Development, LLC $5,129.00 08/28/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424240
Principal investigator 1 ModernaTX, Inc. $118.56 08/28/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007884
Principal investigator 1 Janssen Research & Development, LLC $1,510.00 08/25/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423900
Principal investigator 1 Janssen Research & Development, LLC $5,780.00 08/25/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424249
Principal investigator 1 Janssen Research & Development, LLC $12,650.00 08/25/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424286
Principal investigator 1 Janssen Research & Development, LLC $800.00 08/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175423946
Principal investigator 1 Janssen Research & Development, LLC $1,080.00 08/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424308
Principal investigator 1 Janssen Research & Development, LLC $372.00 08/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424411
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 08/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423869
Principal investigator 1 Janssen Research & Development, LLC $755.00 08/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423917
Principal investigator 1 Janssen Research & Development, LLC $3,020.00 08/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424147
Principal investigator 1 Janssen Research & Development, LLC $669.00 08/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424389
Principal investigator 1 Janssen Research & Development, LLC $568.00 08/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424428
Principal investigator 1 Janssen Research & Development, LLC $223.00 08/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424460
Principal investigator 1 ModernaTX, Inc. $682.00 08/20/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007908
Principal investigator 1 Janssen Research & Development, LLC $6,000.00 08/18/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424405
Principal investigator 1 Genentech, Inc. $2,454.00 08/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567399
Principal investigator 1 Janssen Research & Development, LLC $19,720.00 08/11/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424129
Principal investigator 1 Janssen Research & Development, LLC $6,325.00 08/08/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423840
Principal investigator 1 Janssen Research & Development, LLC $223.00 08/08/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423940
Principal investigator 1 Janssen Research & Development, LLC $10,570.00 08/08/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424051
Principal investigator 1 Janssen Research & Development, LLC $3,775.00 08/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423756
Principal investigator 1 Janssen Research & Development, LLC $12,080.00 08/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423779
Principal investigator 1 Janssen Research & Development, LLC $5,780.00 08/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423883
Principal investigator 1 Janssen Research & Development, LLC $6,325.00 08/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423970
Principal investigator 1 Janssen Research & Development, LLC $16,204.00 08/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424013
Principal investigator 1 Janssen Research & Development, LLC $4,800.00 08/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424333
Principal investigator 1 Janssen Research & Development, LLC $755.00 08/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424537
Principal investigator 1 Janssen Research & Development, LLC $19,079.00 08/01/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175423744
Principal investigator 1 Janssen Research & Development, LLC $1,800.00 07/28/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423818
Principal investigator 1 Genentech, Inc. $4,274.00 07/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566912
Principal investigator 1 Janssen Research & Development, LLC $43,821.00 07/11/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424343
Principal investigator 1 Genentech, Inc. $432.00 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566935
Principal investigator 1 ModernaTX, Inc. $80.00 07/09/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007886
Principal investigator 1 American Regent $123,640.00 07/07/2025 Non-covered Recipient Entity
K2 Medical Research LLC
TPX-100 No dispute reported 06/30/2026 1232689955
Principal investigator 1 Janssen Research & Development, LLC $1,536.00 07/07/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175423790
Principal investigator 1 Janssen Research & Development, LLC $372.00 07/07/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424092
Principal investigator 1 Janssen Research & Development, LLC $239.00 07/07/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424416
Principal investigator 1 Janssen Research & Development, LLC $2,816.00 07/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424000
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $51,858.96 07/01/2025 Non-covered Recipient Entity
K2 Medical Research - Maitland
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235996387
Principal investigator 1 ModernaTX, Inc. $412.19 06/27/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007874
Principal investigator 1 F. Hoffmann-La Roche AG $887.00 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566736
Principal investigator 1 ModernaTX, Inc. $7,419.42 06/18/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007890
Principal investigator 1 ModernaTX, Inc. $1,394.13 06/18/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007922
Principal investigator 1 Janssen Research & Development, LLC $18,975.00 06/16/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423986
Principal investigator 1 Janssen Research & Development, LLC $568.00 06/16/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424116
Principal investigator 1 Janssen Research & Development, LLC $1,250.00 06/16/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424260
Principal investigator 1 Janssen Research & Development, LLC $24,306.00 06/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423856
Principal investigator 1 F. Hoffmann-La Roche AG $4,328.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566492
Principal investigator 1 Janssen Research & Development, LLC $2,616.00 06/06/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424273
Principal investigator 1 ModernaTX, Inc. $8,556.08 05/28/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007902
Principal investigator 1 ModernaTX, Inc. $26,792.35 05/28/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007914
Principal investigator 1 ModernaTX, Inc. $1,394.13 05/28/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007936
Principal investigator 1 Janssen Research & Development, LLC $46,240.00 05/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423812
Principal investigator 1 Janssen Research & Development, LLC $69,360.00 05/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423834
Principal investigator 1 Janssen Research & Development, LLC $24,160.00 05/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423923
Principal investigator 1 Janssen Research & Development, LLC $12,835.00 05/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423934
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 05/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424023
Principal investigator 1 Janssen Research & Development, LLC $21,895.00 05/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424159
Principal investigator 1 Janssen Research & Development, LLC $6,000.00 05/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424354
Principal investigator 1 Janssen Research & Development, LLC $11,560.00 05/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424364
Principal investigator 1 Janssen Research & Development, LLC $5,780.00 05/22/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424506
Principal investigator 1 Eli Lilly and Company $50.59 05/15/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187884318
Principal investigator 1 Janssen Research & Development, LLC $32,556.00 05/12/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424074
Principal investigator 1 Janssen Research & Development, LLC $2,423.00 05/09/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424236
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 05/05/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423888
Principal investigator 1 Janssen Research & Development, LLC $1,800.00 05/05/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424111
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 05/05/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424213
Principal investigator 1 Janssen Research & Development, LLC $2,676.00 05/05/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424421
Principal investigator 1 Janssen Research & Development, LLC $755.00 05/05/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424439
Principal investigator 1 Janssen Research & Development, LLC $119,884.00 05/05/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424483
Principal investigator 1 Janssen Research & Development, LLC $2,681.00 05/02/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424383
Principal investigator 1 ModernaTX, Inc. $2,788.26 04/28/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007876
Principal investigator 1 ModernaTX, Inc. $824.38 04/28/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007888
Principal investigator 1 ModernaTX, Inc. $13,278.72 04/28/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007930
Principal investigator 1 Janssen Research & Development, LLC $2,681.00 04/07/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175423851
Principal investigator 1 Janssen Research & Development, LLC $6,325.00 04/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423805
Principal investigator 1 Janssen Research & Development, LLC $12,650.00 04/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423905
Principal investigator 1 Janssen Research & Development, LLC $32,408.00 04/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423964
Principal investigator 1 Janssen Research & Development, LLC $17,340.00 04/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424032
Principal investigator 1 Janssen Research & Development, LLC $6,325.00 04/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424085
Principal investigator 1 Janssen Research & Development, LLC $40,460.00 04/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424292
Principal investigator 1 Janssen Research & Development, LLC $31,625.00 04/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424359
Principal investigator 1 Janssen Research & Development, LLC $24,306.00 04/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424495
Principal investigator 1 Janssen Research & Development, LLC $69,360.00 04/04/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424520
Principal investigator 1 Janssen Research & Development, LLC $2,007.00 04/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423762
Principal investigator 1 Janssen Research & Development, LLC $1,510.00 04/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423773
Principal investigator 1 Janssen Research & Development, LLC $446.00 04/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423828
Principal investigator 1 Janssen Research & Development, LLC $6,795.00 04/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423976
Principal investigator 1 Janssen Research & Development, LLC $18,975.00 04/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423993
Principal investigator 1 Janssen Research & Development, LLC $24,306.00 04/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424057
Principal investigator 1 Janssen Research & Development, LLC $8,920.00 04/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424134
Principal investigator 1 Janssen Research & Development, LLC $8,102.00 04/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424224
Principal investigator 1 Janssen Research & Development, LLC $446.00 04/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424266
Principal investigator 1 Janssen Research & Development, LLC $1,784.00 04/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424281
Principal investigator 1 Janssen Research & Development, LLC $2,423.00 04/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424298
Principal investigator 1 Janssen Research & Development, LLC $12,650.00 04/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424350
Principal investigator 1 Janssen Research & Development, LLC $12,650.00 04/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424511
Principal investigator 1 Janssen Research & Development, LLC $512.00 03/31/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424046
Principal investigator 1 ModernaTX, Inc. $11,953.51 03/24/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007882
Principal investigator 1 ModernaTX, Inc. $1,394.13 03/24/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007928
Principal investigator 1 ModernaTX, Inc. $12,033.84 03/24/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007934
Principal investigator 1 Janssen Research & Development, LLC $87,639.00 03/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423767
Principal investigator 1 Janssen Research & Development, LLC $4,237.00 03/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424081
Principal investigator 1 Janssen Research & Development, LLC $38,356.00 03/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424122
Principal investigator 1 Janssen Research & Development, LLC $3,568.00 03/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424302
Principal investigator 1 Janssen Research & Development, LLC $97.00 03/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424466
Principal investigator 1 Janssen Research & Development, LLC $755.00 03/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424476
Principal investigator 1 Janssen Research & Development, LLC $6,981.00 03/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424488
Principal investigator 1 Janssen Research & Development, LLC $3,791.00 03/20/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424038
Principal investigator 1 Janssen Research & Development, LLC $3,791.00 03/20/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424139
Principal investigator 1 Janssen Research & Development, LLC $6,690.00 03/20/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424153
Principal investigator 1 Janssen Research & Development, LLC $2,453.00 03/20/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424183
Principal investigator 1 Janssen Research & Development, LLC $26,314.00 03/20/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424189
Principal investigator 1 Janssen Research & Development, LLC $31,220.00 03/20/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424202
Principal investigator 1 Janssen Research & Development, LLC $4,460.00 03/20/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424394
Principal investigator 1 Janssen Research & Development, LLC $42,147.00 03/20/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424399
Principal investigator 1 Janssen Research & Development, LLC $446.00 03/20/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424446
Principal investigator 1 Janssen Research & Development, LLC $2,616.00 03/10/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424068
Principal investigator 1 ModernaTX, Inc. $48,052.34 02/27/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007870
Principal investigator 1 ModernaTX, Inc. $13,020.60 02/27/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007878
Principal investigator 1 ModernaTX, Inc. $25,688.00 02/27/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007898
Principal investigator 1 ModernaTX, Inc. $30,914.25 02/27/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007910
Principal investigator 1 ModernaTX, Inc. $20,911.95 02/27/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007920
Principal investigator 1 ModernaTX, Inc. $1,585.86 02/27/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007932
Principal investigator 1 Eli Lilly and Company $2,732,002.64 02/26/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3954068 IN PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885400
Principal investigator 1 Eli Lilly and Company $3,726.61 02/25/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885398
Principal investigator 1 ABBVIE INC. $1,200.00 02/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
M23-515 - Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1202450895
Principal investigator 1 ABBVIE INC. $1,750.00 02/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
M23-515 - Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1202450899
Principal investigator 1 Eli Lilly and Company $93,596.10 02/10/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886706
Principal investigator 1 Janssen Research & Development, LLC $18,701.00 02/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175423797
Principal investigator 1 Janssen Research & Development, LLC $1,338.00 01/27/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423823
Principal investigator 1 Janssen Research & Development, LLC $3,345.00 01/27/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423846
Principal investigator 1 Janssen Research & Development, LLC $603,327.00 01/27/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423859
Principal investigator 1 Janssen Research & Development, LLC $330.00 01/27/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424104
Principal investigator 1 Janssen Research & Development, LLC $918,317.00 01/27/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424165
Principal investigator 1 Janssen Research & Development, LLC $3,122.00 01/27/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424452
Principal investigator 1 ModernaTX, Inc. $32,361.78 01/23/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007868
Principal investigator 1 ModernaTX, Inc. $75,519.48 01/23/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007880
Principal investigator 1 ModernaTX, Inc. $5,576.52 01/23/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007892
Principal investigator 1 ModernaTX, Inc. $16,899.79 01/23/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007894
Principal investigator 1 ModernaTX, Inc. $22,421.16 01/23/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007904
Principal investigator 1 ModernaTX, Inc. $11,658.40 01/23/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007918
Principal investigator 1 ModernaTX, Inc. $17,444.46 01/23/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007926
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $120,982.30 01/22/2025 Non-covered Recipient Entity
K2 Medical Research
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235996401
Principal investigator 1 Eli Lilly and Company $20,819.08 01/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3954068 IN PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187884356
Principal investigator 1 Eli Lilly and Company $20,347.00 01/21/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885546
Principal investigator 1 Eli Lilly and Company $40,164.53 01/20/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187885602
Principal investigator 1 Janssen Research & Development, LLC $503,984.00 01/20/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424097
Principal investigator 1 Janssen Research & Development, LLC $17,781.00 01/17/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424196
Principal investigator 1 Eli Lilly and Company $222,900.00 01/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187884358
Principal investigator 1 Eli Lilly and Company $2,219,938.00 01/13/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885810
Principal investigator 1 Janssen Research & Development, LLC $512.00 01/10/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424218
Principal investigator 1 Janssen Research & Development, LLC $1,024.00 01/10/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175424370
Principal investigator 1 Eli Lilly and Company $660.12 01/09/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885590
Principal investigator 1 Eli Lilly and Company $2,385,770.00 01/07/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187885566
Principal investigator 1 Eli Lilly and Company $646,958.00 01/07/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187886704
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $293,682.34 01/03/2025 Non-covered Recipient Entity
K2 Medical Research - Maitland
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease No dispute reported 06/30/2026 1235996385
Principal investigator 1 ModernaTX, Inc. $4,000.00 01/03/2025 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007906